Ovarian cancer is a condition where the cancer can recur despite a complete or partial response to surgical and chemo therapies. With this in mind, the treatment of this condition does not always end upon the response to the primary therapy. To some chosen patients, a recommendation for maintenance therapy can be done in order to control the condition for an extended time. Niraparib 100mg capsule is an orally administered PARP inhibitor, which serves as the maintenance therapy in some patients having advanced forms of ovarian, fallopian, or primary peritoneal cancer.
What Is Niraparib and How Is It Used in Ovarian Cancer?
It is an agent that falls under the category of targeted drug therapy, and it is a PARP inhibitor, which functions by interfering with enzymes associated with DNA repair to make cancer cells more susceptible to drugs. It is a maintenance treatment for specific adult patients with cancer of the ovaries, fallopian tubes, or primary peritoneum after response to platinum-based chemotherapy.
Can Medicine Help Reduce the Risk of Ovarian Cancer Recurrence?
The medicine has exhibited promising clinical effects as a maintenance therapy for the management of ovarian cancer. It has been observed that Niraparib is able to increase the time of progression-free survival among patients by keeping them disease progression free after responding to platinum-based chemotherapy.
What Are the Potential Benefits of This Maintenance Therapy?
The administration of the medicine to eligible patients may be associated with the following advantages:
- The ability to control the cancer for a prolonged period of time.
- The ability to maintain the efficacy of platinum-based chemotherapy.
- The oral treatment that is easy to take.
- Personalized therapy for patients whose tumors are susceptible to PARP inhibition.
It should be noted that the capsule has different effects on different patients and does not guarantee that ovarian cancer will not recur.
What Side Effects Can Occur With The Therapy?
The capsule may have side effects that need close monitoring by a physician. Some of the side effects include:
- Thrombocytopenia (platelets deficiency)
- Anemia (red blood cells deficiency)
- Nausea
- Fatigue
- Constipation
- Hypertension
Physicians need to monitor the levels of blood during the treatment. Patients need to report any cases of unexpected bleeding, extreme tiredness, shortness of breath, and fever.
Conclusion
The maintenance therapy can be considered as a way to reduce the chances of disease progression or recurrence in properly chosen patients, especially in cases where it is used as maintenance treatment following sensitivity to platinum-based chemotherapy. It is important as an inhibitor of DNA repair mechanisms that occur via the activity of PARP enzymes. However, niraparib in ovarian cancer treatment cannot serve as a guarantor against recurrence of the condition, and whether it is appropriate or not for a particular patient depends on his/her BRCA/HRD status, prior treatment, responsiveness to chemotherapy, and overall state of health.
FAQs
1. Is the medicine a cure for ovarian cancer?
The use of the capsule is mainly for maintenance purposes. This is intended to help in slowing the progress of the disease and managing it in appropriate patients but without offering a cure.
2. What is the duration of this treatment?
The drug is typically administered until the cancer relapses or there are side effects.
